TAGAMET HB 200 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tagamet Hb 200, and what generic alternatives are available?
Tagamet Hb 200 is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in TAGAMET HB 200 is cimetidine. There are twenty-five drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cimetidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tagamet Hb 200
A generic version of TAGAMET HB 200 was approved as cimetidine by MYLAN on May 17th, 1994.
Summary for TAGAMET HB 200
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 178 |
| Clinical Trials: | 6 |
| Patent Applications: | 4,079 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | TAGAMET HB 200 at DailyMed |
Recent Clinical Trials for TAGAMET HB 200
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institutes of Health (NIH) | Early Phase 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Early Phase 1 |
| Washington State University | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for TAGAMET HB 200
US Patents and Regulatory Information for TAGAMET HB 200
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | TAGAMET HB 200 | cimetidine | SUSPENSION;ORAL | 020951-001 | Jul 9, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
